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AbstrACt
Introduction Pain constitutes a major component of 
the global burden of diseases. Recent studies suggest 
a strong genetic contribution to pain susceptibility and 
severity. Whereas most of the available evidence relies on 
candidate gene association or linkage studies, research 
on the genetic basis of pain sensitivity using genome-
wide association studies (GWAS) is still in its infancy. 
This protocol describes a proposed GWAS on genetic 
contributions to baseline pain sensitivity and nociceptive 
sensitisation in a sample of unrelated healthy individuals 
of mixed Latin American ancestry.
Methods and analysis A GWAS on genetic contributions 
to pain sensitivity in the naïve state and following 
nociceptive sensitisation will be conducted in unrelated 
healthy individuals of mixed ancestry. Mechanical and 
thermal pain sensitivity will be evaluated with a battery of 
quantitative sensory tests evaluating pain thresholds. In 
addition, variation in mechanical and thermal sensitisation 
following topical application of mustard oil to the skin will 
be evaluated.
Ethics and dissemination This study received ethical 
approval from the University College London research 
ethics committee (3352/001) and from the bioethics 
committee of the Odontology Faculty at the University 
of Antioquia (CONCEPTO 01–2013). Findings will be 
disseminated to commissioners, clinicians and service 
users via papers and presentations at international 
conferences.
IntroduCtIon
Pain constitutes a major component of the 
global burden of diseases, with lower back 
and neck pain representing the single leading 
cause for years lived with disability followed 
closely by migraine and other musculoskeletal 
disorders.1 Pain is a multidimensional experi-
ence involving a highly complex interaction 
of physical, biochemical, physiological, cogni-
tive, emotional, behavioural and sociocultural 
factors. Many studies have identified genetic 
factors in a range of chronic pain conditions.2 
Importantly, a growing number of studies in 
patient populations suggest that genetics is an 
important contributory factor to pain suscep-
tibility and severity.2–4 Of note, twin studies 
using either clinical pain outcomes or exper-
imental pain models suggest that sensitivity 
to pain has a heritability of up to 55%.5–10 
Interestingly, the heritability varies greatly 
depending on the clinical pain outcome or 
the sensory modality tested in experimental 
pain models.7 There is evidence that different 
sensory modalities may have distinct genetic 
components contributing to their variance 
in humans,10 and this is consistent with 
animal models which underline the distinct 
neurobiology mediating different sensory 
modalities.11 
A powerful technology for identifying 
genetic determinants of human complex 
phenotypes is genome-wide association 
studies (GWAS). However, GWAS analyses 
strengths and limitations of this study
 ► We propose a genome-wide association study of 
both baseline pain sensitivity as well as nociceptive 
sensitisation.
 ► The study will be conducted in an admixed pop-
ulation in Colombia, with variable proportions of 
European, Native American and sub-Saharan African 
ancestry.
 ► Phenotypic data will be collected by a single trained 
examiner, thus producing high-quality measures.
 ► Because we are focusing on highly reproducible 
pain phenotypes obtained at a single centre, our 
initial sample size is limited to 1500–2000 partici-
pants. This will allow us to identify only genetic vari-
ants that have intermediate and large (but not small) 
effect sizes.
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of pain remain limited, mainly due to the high numbers 
of individuals required to enable adequate power, and 
the complexities of accurately phenotyping traits that 
ultimately represent a personal subjective perception.2 
In contrast to disease cohorts where pain variation may 
be influenced by the severity of the disease process or its 
treatment, experimental pain studies measuring baseline 
pain sensitivity have the advantage of studying one stim-
ulus in a standard condition (eg, controlling intensity, 
location and stimulus duration). To date, several candi-
date gene studies have been performed to determine 
genetic influences on human pain sensitivity using exper-
imental pain models,5–9 12 13 however, to our knowledge, a 
full GWAS has not yet been reported. One genome-wide 
study evaluated association for single nucleotide polymor-
phisms (SNPs) revealed by exome sequencing in a subset 
of twins cohort that were identified as having particularly 
high or low heat pain sensitivity. Using pathway analysis, 
there was significant enrichment for variants in genes of 
the angiotensin pathway.14 Whereas a direct link between 
experimental pain sensitivity and clinical pain severity is 
often not present,15 there is some evidence that findings 
from experimental pain models can be predictive of clin-
ically relevant pathological pain such as postoperative 
pain.16 Irrespective of the association between experi-
mental and pathological pain, understanding the genetic 
influences on experimental pain sensitivity will provide 
important biological insights into the mechanisms under-
lying pain sensitivity.
An important drawback of most genetic studies in the 
pain field so far is that they have been performed mostly 
in populations of European ancestry, thus, they have 
explored only a small fraction of human phenotypic and 
genetic diversity.17 18 This is important in the study of pain 
as recent studies point to variable pain thresholds for 
European Americans, African Americans and Latinos.19–21 
However, it is not clear if this variation in pain thresholds 
relates to differences in neurobiological mechanisms or 
other factors such as social or cultural22 parameters. In 
addition, recent studies suggest that a phenotype associ-
ated with increased sensitisation of the nociceptive system 
due to temporal summation may render people vulner-
able to developing clinically relevant pain.23 However, 
most studies focus on pain phenotyping in the naïve state 
rather than sensitised state; only a handful of studies have 
investigated a genetic component underlying nociceptive 
sensitisation.7 24 We, therefore, intend to use an algogen 
(allyl isothiocyanate [AITC], an agonist of the ligand 
gated ion channel TRPA1) in order to sensitise the noci-
ceptive system to replicate the changes that could occur 
in pathological pain states.
This protocol proposes a GWAS on genetic contribu-
tions to baseline pain sensitivity and nociceptive sensi-
tisation in a sample of unrelated healthy individuals of 
mixed European/Native American/African ancestry. 
We will evaluate baseline cutaneous pain thresholds as 
well as the variation in sensitisation following mustard 
oil (AITC) application, a controlled model of tissue 
injury. We hypothesise that we will identify SNPs asso-
ciated with experimental pain stimuli in the naïve and 
sensitised state. Elucidating the genetic basis of pain vari-
ation has the potential to reveal targets for future anal-
gesic development. This can be translated into improved 
pain management potentially tailored to an individual’s 
pain risk or resilience, including sensitivity differences 
between different human populations.
MEthods And AnAlysIs
This GWAS follows the Strengthening the Reporting of 
Genetic Association Studies guidelines.25 A flow chart of 
the study procedure is detailed in figure 1.
Participants
Healthy participants aged 18–40 will be recruited in 
Medellin, Colombia via public noticeboards at local 
Universities, distribution of flyers and through the local 
print media. In addition, we are inviting previous partici-
pants from the Consortium for the Analysis of the Diver-
sity and Evolution of Latin America (CANDELA)26 GWAS 
to participate in this project.
Recruiting healthy young participants has advantages 
in GWAS studies. They are less likely to have undetected 
illnesses or other problems that may influence their 
biological pathway of pain sensitivity. Young people will 
also have less overall accumulated exposure or risks from 
environmental (external) factors which may affect their 
pain sensitivity. Such factors increase the overall variability 
of participants’ pain perception response and reduce the 
power of detecting genetic causes. Since most traits are 
affected by a combination of genetic and environmental 
factors, many studies including CANDELA tend to use 
young participants for genetic variant discovery.27
Participants will be excluded if they have chronic pain 
or any chronic medical condition (eg, diabetes, neuro-
degenerative, musculoskeletal or psychiatric conditions). 
Participants currently taking analgesics, anti-inflammato-
ries, opioids, antihistamines, antidepressants or antiepi-
leptic drugs will be excluded. Women who are pregnant 
or in their menstrual phase (self-report) will be excluded 
from the study. Participants will be advised to not smoke 
or consume coffee within 1 hour of testing, and to avoid 
psychoactive substances or alcohol within 8 hours prior 
to testing. Further exclusion criteria include current or 
past self-inflicted injuries, as well as dermatomal, trau-
matic or infectious conditions affecting the arm, and a 
history of severe allergic reactions to any kind of medi-
cation, materials, food or insect bites. Participants with 
moderate to severe anxiety (≥25 on the Hamilton Anxiety 
Rating Scale28) or severe depression (>15 on the 16-item 
Quick Inventory of Depressive Symptomatology Self-Re-
ported (QIDS-SR16)29 will be excluded from the study. 
Recruitment started in January 2013 and is predicted to 
take approximately 5–7 years.
Procedure
Participants will attend a single appointment at the quanti-
tative sensory testing (QST) laboratory at the Universidad 
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Figure 1 Study procedure. The graph details the study procedure from recruitment to data analysis. Yellow boxes represent 
new procedures; green boxes indicate data generation and collection; blue boxes indicate a procedural step.  AITC, allyl 
isothiocyanate; BMI, body mass index; CANDELA, Consortium for the Analysis of the Diversity and Evolution of Latin America; 
CDT, cold detection thresholds; GWAS, genome-wide association study; HPT, heat pain threshold; MPT, mechanical pain 
threshold; PCs, principal components; PPT, pressure pain threshold; QST, quantitative sensory testing; TSL, thermal sensory 
limen; VDT, vibration detection threshold; VAS, Visual Analogue Scale; WDT,  warm detection thresholds; WUR, wind-up ratio.
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de Antioquia, Medellín. Following informed consent, age 
and self-reported gender will be recorded and partici-
pants will answer questions regarding their self-reported 
ancestry (see online supplementary appendix 1). Height 
and weight will be measured and body mass index (BMI) 
calculated. Since psychological factors such as anxiety 
can influence pain perception during experimental pain 
testing,30 participants will complete the Spanish version 
of the Hamilton Anxiety Rating Scale and the QIDS-SR16. 
The QIDS-SR16 has acceptable internal consistency and 
moderate to strong concurrent validity compared with 
other depression scores31 and its Spanish version shows 
adequate test–retest reliability and high internal consis-
tency.32 The Hamilton Anxiety Rating Scale has shown to 
have high inter-rater and test–retest reliability33 and good 
construct validity.34
Evaluation of sensory function in the naïve state
We will determine sensory function in the naïve state 
and following nociceptive sensitisation. Baseline sensory 
function will be evaluated using specific static and 
dynamic QST. These include cold detection threshold 
and warm detection thresholds, thermal sensory limen 
and heat pain thresholds (HPT) using a ThermoTester 
(Q-sense, Medoc, Israel, 30×30 mm thermode size). 
Recording of thermal thresholds will strictly follow 
published QST guidelines.35 Mechanical pain thresh-
olds (MPT) will be evaluated using a 20 piece von Frey 
hair set (Touch Test, North Coast, USA) which exerts 
differing forces (9.8, 13.7, 19.6, 39.2, 58.8, 78.5, 98.1, 
147.1, 255.0, 588.4, 980.7, 1765.2, 2942.0 mN). The von 
Frey hairs will be applied at a rate of 2 s on, 2 s off in 
ascending order starting from 9.8mN baseline stimulus 
until participants first perceive the stimulus as sharp 
(pricking). Subsequently, the hairs will be applied in 
descending order until the stimulus is perceived as 
blunt. The geometric mean of five series of ascending 
and descending stimuli is defined as the MPT. Wind-up 
ratio will be determined with numerical pain ratings on 
a Visual Analogue Scale (VAS 0–100) for a single stim-
ulus followed by the average pain rating for a train of 
10 stimuli applied at 1 Hz within the same 1 cm2 using 
a 255 mN von Frey hair. This will be repeated five times 
and the ratio will be established as the mean rating of the 
trains of stimuli divided by the mean rating of the single 
stimuli. Vibration detection thresholds (VDT) will be 
determined by recording the mean of 3 disappearance 
thresholds with a Rydel-Seiffer tuning fork. Pressure 
pain thresholds (PPT) will be recorded in triplicate with 
a manual algometer (Wagner Instruments, Greenwich, 
Connecticut, USA) and their mean used for analysis.
The side to be tested will be randomised and patients 
will first be familiarised with the sensory tests on the 
forearm on the control side, before performing the actual 
measurements on the test arm. All tests will be performed 
halfway over the volar side of the forearm except for VDT 
(ulnar styloid) and PPT (thenar muscles).
Mustard oil evoked nociceptive sensitisation
After the baseline sensory measures, an acetate template 
will be used to mark a star with eight spokes each 
containing eight points at 1 cm increments on the volar 
forearm (figure 2). The skin temperature will be stan-
dardised by placing the 32°C warm thermode over 
the center of the star for 5 min before starting. We will 
then apply a sensitisation paradigm using mustard oil 
(AITC (Sigma), diluted at 30% in olive oil) as previously 
performed.36 AITC, the active component of mustard oil, 
activates the ion channel TRPA1 and evokes skin flare and 
nociceptive sensitisation.37 A small cotton swab soaked in 
mustard oil will be applied to a 0.64 cm2 area on the volar 
forearm and held in place with a Tegaderm (3M) for 
Figure 2 Method to determine area of flare, punctuate 
hyperalgesia and allodynia. (A) An acetate template is used to 
mark a star with eight spokes containing eight points at 1 cm 
increments on the volar forearm. (B) A small cotton swab 
soaked in 30% mustard oil is applied in the center of the 
star and (C) held in place with a Tegaderm for 10 min. During 
this time, pain scores are recorded every 30 s. (D and E) 
After removal of the mustard oil, the skin flare will be marked 
and the area calculated. (F) The area of brush-evoked and 
punctuate hypersensitivity will be determined with a brush 
and a 98.1 mN von Frey hair respectively (pictured) by testing 
potential hypersensitivity at each point on the eight spokes.
 o
n
 18 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025530 on 20 April 2019. Downloaded from 
5Schmid AB, et al. BMJ Open 2019;9:e025530. doi:10.1136/bmjopen-2018-025530
Open access
10 min.36 During this time, pain scores will be recorded 
every 30 s using an electronic VAS ranging from 0 to 100. 
After 10 min, the mustard oil will be removed and the area 
of the skin flare will be recorded to the nearest 0.5 cm at 
each spoke.7 Eight triangular shapes will be created by 
joining the points on adjacent spokes and the total area 
will be calculated by adding all triangular segments. The 
area of mustard oil application will be subtracted from 
the total area to determine the area of secondary flare 
(flare area).
After mapping of the flare, the area of brush-evoked 
hypersensitivity will be determined with a brush (Nr 5 
Senselab, Somedic, Sweden) by applying 1 cm long strokes 
at each of the points on the eight spokes, starting from 
the outside and moving towards the sensitised centre. The 
area of punctuate hypersensitivity will be determined with 
a 98.1 mN filament (Bailey Instruments, UK) following 
the same procedure.36 As for the flare, the primary area 
of mustard oil application will be subtracted from both 
hypersensitive areas such that the recorded areas repre-
sent secondary hyperalgesia/hypersensitivity.
Following mustard oil sensitisation, the MPT and HPT 
will be repeated using the same methods as described 
above. All postsensitisation tests will be performed within 
5 min of mustard oil removal.
reliability of naïve and sensitised sensory function protocol
To determine intratester reliability, we repeated the 
sensory function protocol performed by the same inves-
tigator in n=12 healthy volunteers on two different occa-
sions within 2–6 weeks. Intraclass correlation coefficients 
(3.1) revealed good to excellent agreement for all sensory 
testing variables (table 1).38
Genotyping
Each participant will donate blood or saliva (Oragene 
OG-500, Genotek, Canada) for DNA extraction. DNA 
samples will be genotyped on the Illumina HumanOm-
niExpress chip containing ~700 000 markers. In volun-
teers who already participated in the CANDELA GWAS,39 
genotype data from blood samples genotyped on the 
same chip are already available and will be reused.
Whole-genome genotype data from the Illumina array 
will undergo quality control40 to exclude any markers or 
samples that fail stringent thresholds. Quality metrics 
provided by the genotype calling algorithm in the Illu-
mina GenomeStudio software,41 such as the GenTrain 
score, cluster separation score, and excess heterozygosity 
rates will be used to filter poorly genotyped SNPs. Subse-
quent SNP-level and sample-level quality control thresh-
olds such as missingness will be applied. Sex mismatch 
between records and genetic data of X and Y chromo-
somes will be checked. Only samples and SNPs that pass 
all criteria will be retained for analysis. Details of the 
currently used quality control protocol for CANDELA 
genotyped samples are provided in online supplementary 
appendix 2.
statistical analysis
Sample size calculation
The power for GWAS of experimental pain pheno-
types for varying sample and effect sizes was estimated 
following the formulae described in Visscher et al.42 
Estimated power is shown for a range of effect sizes for 
experimental pain phenotypes taken from existing exper-
imental pain studies. The statistical software R V.3.4.143 
was used to perform the calculations and produce the 
figures. The codes are published on https:// github. com/ 
kaustubhad/ gwas- power.
In whole-genome SNP-based GWAS studies, the asso-
ciation analysis is usually conducted with a multivar-
iate linear regression model, where the trait values are 
regressed onto an SNP genotype (with additive coding) 
and other covariates which commonly include age, 
gender, BMI and genetic principal components (PCs). 
The p value threshold39 42 for genome-wide significant 
associations is commonly 5×10−8, while the threshold 
for a suggestive significant association is commonly 10−5. 
Formulae to calculate power in GWAS with genome-wide 
and suggestive significance thresholds are presented in 
online supplementary appendix 3, and power calculated 
for the current GWAS setting is shown in figure 3.
Figure 3A shows estimated power (in percentage) as 
a heatmap under the standard GWAS settings of using 
whole-genome genotyping data and a p value significance 
threshold of 5×10−8. Sample size (n) varies from 100 to 
5000, while the proportion of trait variance explained by 
the marker (q2, in percentage) varies from 0.01% to 6%. 
As sample size increases, power increases quickly for a 
range of trait variance values to reach 100%.
Figure 3B shows estimated power (in percentage) under 
the same settings but a suggestive p value significance 
Table 1 Intratester reliability of sensory function protocol
Intraclass 
correlation 
coefficients  95% CI P value
CDT 0.728 0.277 to 0.914 0.003
WDT 0.764 0.351 to 0.927 <0.0001
TSL 0.638 0.161 to 0.878 0.005
HPT 0.752 0.339 to 0.922 0.002
MPT 0.928 0.767 to 0.979 <0.0001
WUR 0.634 0.113 to 0.880 0.012
VDT 0.956 0.860 to 0.987 <0.0001
PPT 0.734 0.305 to 0.915 0.002
VAS 0.893 0.667 to 0.970 <0.0001
Flare area 0.610 0.095 to 0.869 0.015
Brush-evoked allodynia 0.756 0.365 to 0.922 0.001
Punctuate hyperalgesia 0.615 0.094 to 0.871 0.013
Postsensitisation MPT 0.941 0.808 to 0.983 <0.0001
Postsensitisation HPT 0.758 0.339 to 0.924 0.002
CDT, cold detection threshold; HPT, heat pain threshold; MPT, mechanical 
pain threshold; PPT, pressure pain threshold; TSL, thermal sensory limen; 
VDT, vibration detection threshold; VAS, Visual Analogue Scale; WDT, warm 
detection threshold; WUR, wind-up ratio.
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threshold of 10−5. As expected, power is higher at similar 
sample and effect sizes for this less stringent threshold.
Simplified power estimates are shown as power curves 
in figure 3C,D for the expected sample sizes for this 
study. Figure 3C shows expected power at genome-wide 
and suggestive significance thresholds for a sample size 
of n=1500 at varying effect sizes, while figure 3D shows 
estimated power for a sample size of n=2000.
The range of trait variance has been taken from Doeh-
ring et al,44 which provides estimates for the proportion 
of trait variance explained by an SNP for several exper-
imental pain phenotypes and multiple markers. The 
Figure 3 Estimated power (in percentage) under the standard genome-wide association studies (GWAS) settings of using 
whole-genome genotyping data. (A) Estimated power (in percentage) as a heatmap, setting the significance threshold at 5×10−8, 
the commonly used threshold for genome-wide significance in GWAS studies. (B) Estimated power with the significance 
threshold set at 10−5, the commonly used threshold for suggestive significance. In panels A-B, the x-axis denotes a range of 
sample sizes (n) in a GWAS, the y-axis represents the proportion of trait variance (q2) explained by a marker. Power of detecting 
the marker at a specific (n, q2) combination is represented by a colour gradient. Contour lines for power at 10% intervals are 
also shown. Panels C-D shows power curves for the expected sample sizes for this study. (C) Expected power at genome-wide 
and suggestive significance thresholds for a sample size of n=1500. (D) Estimated power for a sample size of n=2000. In Panels 
C-D, the x-axis denotes the proportion of trait variance (q2) explained by a marker, and y-axis represents estimated power (in 
percentage). The two curves correspond to the two commonly used GWAS thresholds. In each panel, the point for 80% power 
is indicated with a green triangle, so that the necessary parameter configurations can be read from the graph. In panels A-B, the 
contour corresponding to 80% power is also marked in green.
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values ranged from 0.02% to 6%. Some of the traits were 
the same as the traits investigated here, while some other 
traits were different. Nevertheless, the distributions of 
trait variance for the two groups of traits are very similar, 
as seen in figure 4A.
Power of a GWAS depends on the allele frequency of 
the SNPs through their effect on the test statistic. While 
the majority of GWAS studies are conducted in Europe-
an-origin individuals, including the experimental pain 
study used to determine sample size here,44 our popula-
tion of interest is an admixed Latin American population. 
Therefore, we wanted to assess the distribution of allele 
frequencies in Europeans versus Colombians for SNPs 
studied for or associated with experimental pain in various 
studies.44 45 Minor allele frequencies were obtained for 
all such reported SNPs from the 1000 Genomes project 
database17 for Western Europeans (from Britain (GBR), 
Utah residents from Northern and Western Europe 
(CEU), Spain (IBS), and Tuscany in Italy (TSI)) and 
Colombians (from Medellin in Colombia, (CLM), where 
this study will be performed). Allele frequency distribu-
tions for both Europeans and Colombians are shown in 
figure 4B. The two distributions are quite similar, with the 
Colombian distribution slightly more spread out. This is 
somewhat expected as the Colombians have on average 
60% European (Spanish) ancestry.26 Having a well spread 
out distribution of allele frequencies is important in a 
GWAS as low-frequency alleles have lower power for a 
given sample and effect size.46 Here, the comparison to 
European allele frequency distribution suggests that the 
current Colombian cohort will have nearly equivalent 
power to any European-based cohort. In contrast to Euro-
pean-only cohorts though, our cohort will have the advan-
tage that alleles present in other continental populations 
such as sub-Saharan Africans or Native Americans that are 
not present in Europeans would also be detectable in a 
GWAS, and could be followed up in replication cohorts 
of specific ethnicities.
The CANDELA project includes genotpyes of ~2000 
patients from Medellin. We anticipate to contact and 
phenotype 50%–75% of these participants as well as 
contacting an additional 500 participants to bring the 
initial sample to 1500–2000.
Data analysis plan
The cleaned genetic data will first be merged with refer-
ence samples worldwide, such as the 1000 Genomes 
Project,17 Simons Genome Diversity Project,47 Estonian 
Biocentre Human Genome Diversity Panel,48 and addi-
tional European and Native American samples that 
are particularly relevant for Latin American popula-
tions.49 The merged dataset will be checked for genetic 
outliers, through genetic PCs and continental ancestry 
proportions (using supervised Admixture50), and for 
unexpected genetic similarities. These steps can often 
detect any sample misplacement or contamination, 
which might be reflected in sex mismatch, unexpected 
genetic similarities or inflated heterozygosity rates.40 51 
Genetic ancestry estimates will be compared with self-re-
ported ancestry information (see online supplementary 
appendix 1), particularly for genetic outliers or samples 
showing unexpected results. Participants self-reporting 
for ethnicities rare in Colombians, such as East Asian 
or South Asian, would also be excluded as outliers. The 
authors have extensive experience in conducting associ-
ation analysis in admixed populations, including several 
GWAS publications on a wide range of phenotypes which 
contain detailed protocols on how to conduct such anal-
yses.27 39 52 53 Further details of the currently used quality 
control protocol for CANDELA samples53 are provided in 
online supplementary appendix 2. 
The genetic data allow estimation of the narrow-sense 
heritability of any quantitative trait, which is the fraction 
of trait variance that is explained by the genetic data. 
Estimates of heritability, obtained using the software 
GCTA,54 will provide an idea of which traits have more 
of a biological basis versus which are more environmen-
tally determined, and thus which traits would be more 
amenable to genetic analysis for discovery of associated 
genetic variants. Note however that relatively precise esti-
mate (low SDs) of heritability by this method requires 
several thousand samples,52 so the currently proposed 
Figure 4 (A) Distributions of trait variance explained by a single marker from Doehring et al44 for traits included in our study 
and those not included. (B) Allele frequency distributions of loci associated with experimental pain in previously published 
cohorts, for Europeans and Colombians.
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sample size might be underpowered to estimate herita-
bility accurately.
To facilitate better identification of associated loci, the 
genotype data will be imputed to approximately 10 million 
loci using the 1000 Genomes phase 3 imputation refer-
ence panel52 by first haplotype phasing using SHAPEIT255 
and then imputation using Impute2.56 Quality control of 
the imputed genotypes will be performed using recom-
mended thresholds on imputation quality score, concor-
dance metrics and proportion of high-probability calls. 
Details of the currently used imputation protocol for 
CANDELA samples52 are provided in online supplemen-
tary appendix 2.
GWAS studies will be conducted in Plink257 to perform 
single-locus association studies for each trait individu-
ally, across the whole genome in an additive multivar-
iate linear regression model.42 Covariates will be used 
in the regression to adjust for any other sources of trait 
variability, such as basic variables like age, sex, and BMI, 
and genetic PCs will be used to control for population 
substructure.52 58
The number of genetic PCs to be included in the regres-
sion depends on the sample composition, such as varia-
tion in ancestry and presence/absence of genetic outliers. 
It would be determined by inspecting the proportion of 
variance explained by each PC (displayed on a scree plot) 
and by checking PC scatter plots.
In addition to being used as exclusion criteria, anxiety 
and depression scores could be used as covariates in 
GWAS. The exact set of covariates to be used will be deter-
mined based on initial diagnostic analyses such as correla-
tion analysis.
These single-locus association results, obtained as 
p values, will be visualised via the Manhattan plot. 
Commonly used p value thresholds for selecting associ-
ated loci are 5×10−8 for genome-wide significance and 
10−5 for suggestive significance.42
An extension of this additive multivariate linear 
regression model, still within the single-trait single-locus 
setting, called the mixed linear model analysis which 
better controls for any cryptic relatedness or population 
substructure, will also be performed in GCTA.54
There are several extensions of the single-trait single-
locus association studies that increase power for detecting 
associated loci: combining several related traits that may 
share a biological basis, using multivariate Wald tests as 
implemented in MultiPhen59; or gene-based tests that 
combine signals across all loci in a gene to increase signal 
strength and reduce the burden of multiple testing, such 
as set-based models implemented in Plink257 or fastBAT 
implemented in GCTA.60 The admixed nature of the 
sample might be used in detecting associations by the 
method of admixture mapping,61 though the potential 
of success of this method in detecting associated variants 
depends on the extent of stratification of the variant’s 
allele frequency across continents. These analyses might 
help detect additional loci that are underpowered in clas-
sical GWAS due to smaller effect sizes.
Handling of missing data
It might not be possible to record some traits in some 
individuals, even though the completeness of the first 100 
samples suggests that missingness will be low. The single-
trait methods used in traditional GWAS analyses auto-
matically exclude individuals from the analysis of a trait 
who have missing values for that trait. The same applies 
to individuals having missing genotypes for any particular 
SNP. However, genotyping success rate using the Illumina 
HumanOmniExpress chip in the CANDELA cohort is 
very high (>99.8%), so the number of excluded individ-
uals in any analysis would be very low overall.
Some multivariate analyses such as PCs when applied 
on the set of phenotypes require having recorded values 
of all phenotypes for an individual. Instead of using the 
subset of individuals who have the complete set of pheno-
types recorded, which would incur some loss in sample 
size, the missing phenotype data for each individual will 
be imputed following standard statistical procedures as 
implemented in the R package ‘mice’.62 When the propor-
tion of missing data is small, imputation is preferable in 
such multivariate analyses than sample exclusion, and is 
routinely applied to genetic data such as while calculating 
genetic PCs.58
dIsCussIon
This GWAS including a well-defined cohort of healthy 
participants will provide important insights into the 
genetic aspects underlying experimental pain sensitivity 
in the naïve and sensitised state. This may allow further 
exploration of potential biological mechanisms under-
lying pain sensitivity. Future studies will be required to 
extrapolate these findings to patient populations with 
chronic pain.
Patient and public involvement
No patient involvement is performed during this study.
Ethics and dissemination
Findings will be disseminated to commissioners, clinicians 
and service users via papers and presentations at interna-
tional conferences such as the biennial World Congress 
of International Association for the Study of Pain. We will 
also post our findings to the publicly available  painnet-
works. org database.
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